LLY•benzinga•
Eli Lilly's Investigational Drug Cuts Sticky Cholesterol Levels By Almost 86%
Summary
Eli Lilly's muvalaplin Phase 2 trial showed significant Lp(a) reduction, meeting primary and secondary endpoints with favorable safety data.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 19, 2024 by benzinga